WASHINGTON – Today, the U.S. Drug Enforcement Administration filed its intent to temporarily place 7-hydroxymitagynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act (CSA). Prior to DEA issuing this notice, the Department of Health and Human Services (HHS) confirmed synthetic 7-OH, and the three related substances have no accepted medical use and a high potential for abuse.

Two Notices of Intent (NOI) were sent to the Federal Register on Wednesday, July 1, 2026 . One NOI addresses 7-OH above a specified threshold. The second NOI addresses moving 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16) into Schedule 1 of the CSA.

Once the temporary scheduling orders take effect, the manufacture, distribution, sale, and possession of covered 7-OH substances will become subject to criminal, civil, and administrative provisions of the Controlled Substances Act.

“Today’s action targets highly concentrated, synthetic 7-OH products, which pose…